| Source HCPCS Code |
|
Target NDC Code |
Q5125
Injection, filgrastim-ayow, biosimilar, (releuko), 1 mcg
|
⇄
|
70121-1568-01
RELEUKO 300 MCG/0.5 ML SYRI
|
| Detail Information |
| Relationship Start Date |
11/22/2022 |
| Relationship End Date |
12/31/3999 |
| Number Of Items In Ndc Package |
0.5 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
SYRINGE |
| Route Of Administration |
SQ |
| Billing Units |
ML |
|
|
|
Q5125
Injection, filgrastim-ayow, biosimilar, (releuko), 1 mcg
|
⇄
|
70121-1568-07
RELEUKO 300 MCG/0.5 ML SYRI
|
| Detail Information |
| Relationship Start Date |
04/01/2023 |
| Relationship End Date |
12/31/3999 |
| Number Of Items In Ndc Package |
0.5 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
SYRINGE |
| Route Of Administration |
SQ |
| Billing Units |
ML |
|
|
|
Q5125
Injection, filgrastim-ayow, biosimilar, (releuko), 1 mcg
|
⇄
|
70121-1569-01
RELEUKO 300 MCG/ML VIAL
|
| Detail Information |
| Relationship Start Date |
10/01/2022 |
| Relationship End Date |
12/31/3999 |
| Number Of Items In Ndc Package |
1 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VIAL |
| Route Of Administration |
IJ |
| Billing Units |
ML |
|
|
|
Q5125
Injection, filgrastim-ayow, biosimilar, (releuko), 1 mcg
|
⇄
|
70121-1569-07
RELEUKO 300 MCG/ML VIAL
|
| Detail Information |
| Relationship Start Date |
10/01/2022 |
| Relationship End Date |
12/31/3999 |
| Number Of Items In Ndc Package |
10 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VIAL |
| Route Of Administration |
IJ |
| Billing Units |
ML |
|
|
|
Q5125
Injection, filgrastim-ayow, biosimilar, (releuko), 1 mcg
|
⇄
|
70121-1570-01
RELEUKO 480 MCG/0.8 ML SYRI
|
| Detail Information |
| Relationship Start Date |
11/22/2022 |
| Relationship End Date |
12/31/3999 |
| Number Of Items In Ndc Package |
0.8 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
SYRINGE |
| Route Of Administration |
SQ |
| Billing Units |
ML |
|
|
|
Q5125
Injection, filgrastim-ayow, biosimilar, (releuko), 1 mcg
|
⇄
|
70121-1570-07
RELEUKO 480 MCG/0.8 ML SYRI
|
| Detail Information |
| Relationship Start Date |
04/01/2023 |
| Relationship End Date |
12/31/3999 |
| Number Of Items In Ndc Package |
0.8 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
SYRINGE |
| Route Of Administration |
SQ |
| Billing Units |
ML |
|
|
|
Q5125
Injection, filgrastim-ayow, biosimilar, (releuko), 1 mcg
|
⇄
|
70121-1571-07
RELEUKO 480 MCG/1.6 ML VIAL
|
| Detail Information |
| Relationship Start Date |
11/22/2022 |
| Relationship End Date |
12/31/3999 |
| Number Of Items In Ndc Package |
1.6 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VIAL |
| Route Of Administration |
IJ |
| Billing Units |
ML |
|
|
|
Q5125
Inj, releuko 1 mcg
|
⇄
|
70121-1568-01
Releuko
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q5125
Inj, releuko 1 mcg
|
⇄
|
70121-1569-07
Releuko
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q5125
Inj, releuko 1 mcg
|
⇄
|
70121-1570-01
Releuko
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q5125
Inj, releuko 1 mcg
|
⇄
|
70121-1571-07
Releuko
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|